Related Experiment Videos
Sudden death in patients receiving clozapine treatment: a preliminary investigation
I Modai1, S Hirschmann, A Rava
1Sha'ar Menashe Mental Health Center, Hadera, Israel. menashel1@isdn.net.il
Insights
Clozapine treatment may increase the risk of sudden death, especially in younger, healthier patients. This study found a higher sudden death rate in clozapine-treated patients compared to those on other psychiatric medications.
Area of Science:
- Psychiatry
- Pharmacology
- Public Health
Background:
- Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia.
- The risk of sudden death associated with clozapine treatment remains a subject of debate.
- This study investigates sudden death rates among clozapine-treated patients (CTPs) versus those on other psychiatric agents.
Observation:
- A review of deaths at Sha'ar Menashe Mental Health Center (1991-1997) was conducted.
- Data included sudden deaths, suicides, and disease-related deaths for CTPs and non-CTPs.
- CTPs experiencing sudden death were younger and healthier than non-CTPs.
Findings:
- The sudden death rate was 3.8 times higher in CTPs than non-CTPs.
- Disease-related death rates were 5 times higher in non-CTPs.
- Suicide rates were 3.6 times higher among current CTPs.
Implications:
- Clozapine treatment may pose a higher risk for sudden death compared to other psychiatric medications.
- The findings suggest careful monitoring of CTPs for cardiovascular events and suicide risk.
- Further research with larger sample sizes is warranted due to the limited number of cases.
Abstract:
The risk of sudden death during clozapine treatment is controversial. The authors present a review of sudden deaths that occurred at Sha'ar Menashe Mental Health Center between January 1991 and August 1997. The number of cases of deceased inpatients was retrieved from the hospital's computerized database and divided into three groups: sudden death, suicide, and disease-related death. Copies of mandatory reports of sudden death filed with the Ministry of Health were obtained, and the corresponding patient records were reviewed. The rates of sudden death, suicide, and disease-related deaths were calculated for clozapine-treated patients (CTPs) during and after treatment and for patients treated with other psychiatric agents (non-CTPs). Among 561 CTPs, there were 4 sudden deaths during treatment, 2 sudden deaths after treatment, 2 suicides during treatment, and 2 disease-related deaths during treatment. Among 4918 non-CTPs, there were 14 sudden deaths, 5 suicides, and 86 disease-related deaths, all of which occurred during treatment with other psychiatric agents. CTPs who experienced sudden death were 10.37 years younger and healthier than non-CTPs who experienced sudden death. The sudden death rate was 3.8 times higher for CTPs than for non-CTPs, whereas the rate of disease-related death was 5 times higher for non-CTPs than for CTPs. Contrary to expectations, the rate of suicide among patients currently receiving clozapine in this sample was 3.6 times higher than among non-CTPs. Because CTPs who experienced sudden death were also younger and healthier, it seems that treatment with clozapine may present a greater risk for sudden death than treatment with other psychiatric medications. The limited number of sudden death cases and deaths from other causes should be noted so that these findings are considered with caution.